Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the company opened ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...